Type 1 Diabetes Trial, Recruiting NCT06325202 Sponsor: Milton S. Hershey Medical Center Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Type 1 Diabetes Trial, Recruiting

NCT06325202
Recruiting Not Applicable 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been clinically diagnosed with type 1 diabetes
  • People whose diabetes has lasted 10 years or more
  • People who score 4 or higher on either the Gold Score or Clarke Score, which are tools used to assess whether someone has reduced awareness of low blood sugar episodes
  • People whose C-peptide level (a measure of how much insulin the body still makes on its own) is below 200 pmol/L on a random blood test taken without fasting
  • People whose HbA1c (a measure of average blood sugar over roughly 3 months) is below 10.5%
  • People whose total daily insulin dose is less than 1 unit per kilogram of body weight
  • People who are able to read and speak English, as the cognitive tests and educational materials used in this trial are only available in English

Who may not be able to join:

  • People with medical conditions that the trial investigator determines would limit their ability to participate, such as cognitive difficulties, significant hearing or vision loss, cancer currently being treated, untreated chest pain (angina), or organ failure
  • People with active alcohol or drug misuse, defined as repeated use that causes problems at work, school, or home; repeated use in physically dangerous situations; or repeated alcohol- or drug-related legal issues
  • People with social circumstances that the trial investigator determines would limit their ability to participate, such as homelessness, food insecurity, or lack of adequate support from others
  • People with a seizure disorder not caused by low blood sugar, unless they have been documented as seizure-free for more than 12 months and are on a stable seizure medication plan
  • People with skin conditions that would prevent them from wearing a continuous glucose monitor (CGM) device
  • People who have been exposed to high-dose steroids within one month before enrolling
  • People whose kidney function score (eGFR) is below 45 mL/min/1.73 m²
  • People who have had a type of weight-loss surgery (bariatric surgery) that permanently changes the structure or nerve supply of the gut
  • People with potassium levels in the blood that are too high (above 5.5 mmol/L) or too low (below 3.5 mmol/L)
  • People with a hemoglobin level below 10 g/dL (a measure of red blood cells)
  • People with a medical condition requiring regular or ongoing use of steroid medications (glucocorticoids) at doses higher than what the body would naturally produce
  • People who are pregnant, planning to become pregnant, or currently breastfeeding
  • People with thyroid function test results that the trial investigator considers clinically significant
  • People whose liver enzyme levels (liver transaminases) are more than 3 times the upper limit of normal
  • People who have been hospitalised for a mental health condition in the past year
  • People who have had their adrenal glands removed (adrenalectomy)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Vernon M Chinchilli, PhD, Penn State College of Medicine

Phone: 717-531-0003

Australian sites

University of Melbourne, Fitzroy, Victoria
61 3 9231 2574

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Milton S. Hershey Medical Center
Registry
ClinicalTrials.gov
Start date
3 October 2025
Est. completion
31 July 2029

Where this trial is recruiting

🇦🇺 Australia 🇬🇧 United Kingdom 🇺🇸 United States

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

epinephrine (pg/ml); Towler questionnaire

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov